Development of Long-Acting Local Anesthetics
Lotus Clinical Research Presented at Pain Therapeutics in San Francisco on Development of Long-Acting Local Anesthetics
PASADENA, Calif., November 8, 2018 (Newswire.com) - Lotus Clinical Research is pleased to announce that our Founder and Chief Executive Officer, Dr. Neil Singla, presented at the 12th annual Pain & Migraine Therapeutics Conference in San Francisco, California. Dr. Singla discussed "Development of Long-Acting Local Anesthetics: Clinical Trial Considerations in Phases I-III."
Pain & Migraine Therapeutics is the US’s premier pain conference covering the field of pain research and therapeutics, with opportunities to discuss and learn about the latest advances in the treatment of various types of pain. The conference gathered Scientists, Researchers, Physicians, NIH, Pharmaceutical Companies, and Research Companies in one place to tackle pain and migraine research and development and provided attendees “with thoughtful insight from key industry leaders and academic researchers concerning cutting-edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products.” (https://www.paintherapeuticsummit.com)
Dr. Singa's presentation focused on Development of Long-Acting Local Anesthetics: Clinical Trial Considerations in Phases I-III. Dr. Singla discussed key elements of clinical trial design and conduct for long-acting local anesthetics. An Anesthesiologist by training, Dr. Singla has been in analgesic clinical research since 2001. His presentation covered topics including:
· optimum formulations
· early-phase stopping rules
· dose escalation paradigms
· safety review committee concerns
· proof of concept models
· Phase 3 pivotal models
· and other key issues for these programs
Physicians and patients are increasingly looking for non-opioid ways to control postoperative pain.
“Physicians and patients are increasingly looking for non-opioid ways to control postoperative pain,” indicated Dr. William Schmidt, President of NorthStar Consulting. “While it’s not always possible to provide opioid-free pain control, judicious use of long-acting local anesthetics has already shown promise in reducing patient exposure to postoperative narcotics. There is a significant need for even longer-acting local anesthetics; studies have shown that patients often have less pain overall, fewer side effects, and recover function more quickly when longer-acting local anesthetics are used as part of a comprehensive pain control strategy.”
Dr. Singla also participated in a Panel Discussion with Nathaniel Katz, MD, MS, and Robert H. Dworkin, PhD. on “Designing and Implementing Better Pain Clinical Trials.”
About Lotus Clinical Research: Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments and has played a role in 10 analgesic FDA approvals. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain providing scientific leadership at every step of the development process. In assisting with the advancement of pain therapies, Lotus Clinical Research seeks to invent and operationalize research methods that improve study design and conduct for analgesic trials, which support our mission to help alleviate the opioid crisis in society.
Source: Lotus Clinical Research
Tags: acute pain, analgesic, analgesic clinical trials, chronic pain, clinical research, clinical trials in pain, CRO, local anesthetics, long-acting local anesthetics, opioid epidemic, pain, private equity